4D Lifetec — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

4D Lifetec is an innovative Swiss diagnostics company pioneering a novel blood test for early cancer detection. Its core product, the 4D Lifetest™, leverages proprietary hardware (4D Lifechamber) and AI software (4D LifeAI) to create a standardized, automated workflow. The company holds an extensive IP portfolio with patent protection in key global markets, positioning itself to address the significant unmet need for accessible and reliable early cancer screening. As a private, pre-revenue startup, 4D Lifetec is focused on technology development and validation.

Oncology

Technology Platform

The 4D Lifetest™ platform combines proprietary hardware (4D Lifechamber, an automated Single Cell Gel Electrophoresis chamber) and AI software (4D LifeAI) to create a standardized, non-invasive blood test for early cancer detection. It analyzes immuno-oncological signals, likely focusing on the body's immune response to tumors.

Opportunities

The global liquid biopsy market for early cancer detection is large and growing rapidly, driven by the need for non-invasive, accessible screening tools.

A standardized, cost-effective test could see adoption in routine preventive care and high-risk population screening.

The company's extensive IP portfolio provides a potential barrier to entry for competitors.

Risk Factors

Major risks include the failure of the technology to validate in large-scale clinical trials, intense competition from well-funded players in the liquid biopsy space, and the significant challenges of obtaining regulatory approvals (FDA, CE Mark) and securing adequate funding to reach commercialization.

Competitive Landscape

4D Lifetec operates in the highly competitive liquid biopsy for early cancer detection market, competing against large, well-capitalized companies like Grail (Illumina), Exact Sciences, and Freenome, as well as numerous other startups. Differentiation will require demonstrating superior accuracy, a unique biological signal (immuno-oncological focus), cost advantages, or ease of integration into clinical labs.

More companies in Diagnostics & Precision Medicine →More companies in Switzerland →